Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, multicenter, randomized, open-label, active-controlled trial of trastuzumab deruxtecan (T-DXd), an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician's choice for HER2-Low, unresectable and/or metastatic breast cancer subjects (DESTINY-Breast04)

Next Previous
Trial Profile

A phase 3, multicenter, randomized, open-label, active-controlled trial of trastuzumab deruxtecan (T-DXd), an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician's choice for HER2-Low, unresectable and/or metastatic breast cancer subjects (DESTINY-Breast04)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Paclitaxel
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DESTINY-B04; DESTINY-Breast04
  • Sponsors Daiichi Sankyo Inc

Most Recent Events

  • 08 May 2025 Results assessing Patient-reported outcomes from this study published in the Oncologist
  • 02 Dec 2024 According to Daiichi Sankyo media release, data from this trial will be presented in a poster presentation, on December 11 2024, 12:30 - 2:00 pm at San Antonio Breast Cancer Symposium (#SABCS24).
  • 03 Sep 2024 According to an AstraZeneca media release, clinical data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress, September 13 to 17, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top